Biogen (BIIB) Says First Phase 3 Trial for Oral BG-12 Met Primary Endpoint and All Secondary Endpoints

Biogen (Nasdaq: BIIB) reports positive top-line results from first Phase 3 trial investigating oral BG-12 in multiple sclerosis.

Says define study met primary and all secondary endpoints.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Biogen (BIIB) call put ratio 3.7 calls to 1 put with a focus on September calls
• FDA grants Nuvation Bio fast track status for brain cancer drug
• AC Immune reports early Phase 1 data for NLRP3 inhibitor ACI-19764